COVID-19-associated mucormycosis and treatments

Vetriselvan SUBRAMANIYAN; Rusli Bin NORDIN; Srikumar CHAKRAVARTHI; Shivkanya FULORIA; Neeraj Kumar FULORIA; Hari Kumar DARNAL; Dhanalekshmi Unnikrishnan MEENAKSHI; Shah Alam KHAN; Mahendran SEKAR; Kathiresan V SATHASIVAM; Yuan Seng WU; Usha KUMARI; Kalvatala SUDHAKAR; Rishabha MALVIYA; Vipin Kumar SHARMA

Return

COVID-19-associated mucormycosis and treatments

Author: Vetriselvan SUBRAMANIYAN ¹ ; Rusli Bin NORDIN ¹ ; Srikumar CHAKRAVARTHI ¹ ; Shivkanya FULORIA ² ; Neeraj Kumar FULORIA ² ; Hari Kumar DARNAL ³ ; Dhanalekshmi Unnikrishnan MEENAKSHI ⁴ ; Shah Alam KHAN ⁴ ; Mahendran SEKAR ⁵ ; Kathiresan V. SATHASIVAM ⁶ ; Yuan Seng WU ⁷ ; Usha KUMARI ⁸ ; Kalvatala SUDHAKAR ⁹ ; Rishabha MALVIYA ¹⁰ ; Vipin Kumar SHARMA ¹¹
Author Information

1. Faculty of Medicine, Bioscience and Nursing, MAHSA University
2. Faculty of Pharmacy, Centre of Excellence for Biomaterials Engineering, AIMST University
3. Jeffrey Cheah School of Medicine and Health Sciences, Monash University
4. College of Pharmacy, National University of Science and Technology
5. Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Health Sciences, Universiti Kuala Lumpur Royal College of Medicine
6. Faculty of Applied Science, Centre of Excellence for Biomaterials Engineering, AIMST University
7. Centre for Virus and Vaccine Research, Department of Biological Sciences, School of Medical and Life Sciences, Sunway University
8. Faculty of Medicine, AIMST University
9. School of Pharmaceutical Sciences (LIT-Pharmacy), Lovely Professional University
10. Department of Pharmacy, SMAS, Galgotias University
11. Department of Pharmaceutical Sciences, Gurukul Kangri
Publication Type:Journal Article
Keywords: COVID-19; Immunosuppression; Mucormycosis; Pathogenesis; Treatment
From: Asian Pacific Journal of Tropical Medicine 2021;14(9):401-409
CountryChina
Language:Chinese
Abstract: In the current pandemic, COVID-19 patients with predisposing factors are at an increased risk of mucormycosis, an uncommon angioinvasive infection that is caused by fungi with Mucor genus which is mainly found in plants and soil. Mucormycosis development in COVID-19 patient is related to various factors, such as diabetes, immunocompromise and neutropenia. Excessive use of glucocorticoids for the treatment of critically ill COVID-19 patients also leads to opportunistic infections, such as pulmonary aspergillosis. COVID-19 patients with mucormycosis have a very high mortality rate. This review describes the pathogenesis and various treatment approaches for mucormycosis in COVID-19 patients, including medicinal plants, conventional therapies, adjunct and combination therapies.